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Background: The treatment of spinal cord injury (SCI)-induced neuropathic pain presents a challenging healthcare
problem. The lack of available robust pharmacological treatments underscores the need for novel therapeutic
methods and approaches. Due to the complex character of neuropathic pain following SCI, therapies targeting
multiple mechanisms may be a better choice for obtaining sufficient long-term pain relief. Previous studies in our
lab showed analgesic effects using combinations of an NMDA antagonist peptide [Ser1]histogranin (SHG), and the
mu-opioid peptides endomorphins (EMs), in several pain models. As an alternative to drug therapy, this study evaluated
the analgesic potential of these peptides when delivered via gene therapy.
Results: Lentiviruses encoding SHG and EM-1 and EM-2 were intraspinally injected, either singly or in combination, into
rats with clip compression SCI 2 weeks following injury. Treated animals showed significant reduction in mechanical
and thermal hypersensitivity, compared to control groups injected with GFP vector only. The antinociceptive effects of
individually injected components were modest, but the combination of EMs and SHG produced robust and sustained
antinociception. The onset of the analgesic effects was observed between 1–5 weeks post-injection and sustained
without decrement for at least 7 weeks. No adverse effects on locomotor function were observed. The involvement of
SHG and EMs in the observed antinociception was confirmed by pharmacologic inhibition using intrathecal injection
of either the opioid antagonist naloxone or an anti-SHG antibody. Immunohistochemical analysis showed the presence
of SHG and EMs in the spinal cord of treated animals, and immunodot-blot analysis of CSF confirmed the presence of
these peptides in injected animals. In a separate group of rats, delayed injection of viral vectors was performed in
order to mimic a more likely clinical scenario. Comparable and sustained antinociceptive effects were observed in
these animals using the SHG-EMs combination vectors compared to the group with early intervention.
Conclusions: Findings from this study support the potential for direct gene therapy to provide a robust and sustained
alleviation of chronic neuropathic pain following SCI. The combination strategy utilizing potent mu-opioid peptides with a
naturally-derived NMDA antagonist may produce additive or synergistic analgesic effects without the tolerance
development for long-term management of persistent pain.
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Figure 1 Schematic of construct encoding recombinant peptides.
The schematic shows the features of the construct. The CMV promoter
from lentiviral vector pRRL (pRRLsinPPT.CMV.EM1/EM2/SHG.Wpre) is
followed by the signal sequence preproNGF-β (BamHI-BglII) and the
cDNAs encoding for SHG or EM1 or EM2 (BglII-XbaI). The locations of
forward and reverse gene specific primers used to assess gene
expression are shown by filled and open arrows respectively.
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Long term treatment for neuropathic pain arising from
spinal cord injury (SCI) remains an important health care
problem [1-3]. The mechanisms underlying the develop-
ment of such pain syndromes are complex and an area of
active research [4-10]. SCI patients exhibit a relatively
poor response to traditional analgesics such as opioids
and ketamine [11,12]. In addition the therapeutic doses
are associated with adverse side-effects, especially during
long-term use. As an alternate strategy to side-effect rid-
den monotherapy, additive or synergistic drug combina-
tions that target multiple mechanisms is warranted. Such
drug combinations could provide potent analgesia at
lower doses while reducing side effects of high doses
needed to achieve even modest antinociceptive effects in
SCI patients. Numerous studies have shown enhanced
antinociceptive effects of opioids when used in combin-
ation with NMDA antagonists, suggesting analgesic syner-
gism [13-18]. Additionally reduced tolerance development
to morphine and other μ-opioids has been obtained by
combination with NMDA receptor antagonists [19-25].
Antinociceptive effects of intrathecally administered EM-1
can be significantly enhanced in a synergistic fashion by
NMDA antagonists [26,27]. Thus, the combined adminis-
tration of opioids and NMDA antagonists is promising to
manage difficult pain states. However, for long-term pain
management, there are potential problems associated with
the need for repeated bolus or continual delivery of ex-
ogenous pharmacologic agents which may be overcome
by direct delivery of active drugs to a particular area of
CNS via gene therapy. The goal of this study was to ex-
plore the potential for co-delivery of opioid-active pep-
tides and an NMDA-active peptide via viral vectors to
alleviate SCI pain on a sustained basis.
Endomorphins are amidated tetrapeptides originally iso-
lated from bovine brain. They have high selectivity to-
wards the μ-opioid receptor [28]. Compared to morphine,
endomorphins show more potency in neuropathic pain
conditions and may produce less undesired side effects
[29]. These peptides show a potent, dose- and time-
dependent antinociceptive effect after intraventricular and
intrathecal injection in acute, neuropathic and inflamma-
tory pain models [28,30-32]. Histogranin is a 15-amino
acid naturally occurring peptide which possesses post-
synaptic NMDA receptor antagonist-like activity [33].
Findings in our laboratory suggest that SHG, a stable
analogue of histogranin, attenuates NMDA-mediated
nociception without producing neurotoxicity [34]. No at-
tendant motor dysfunction was observed using a battery
of tests, in contrast to findings with synthetic NMDA
blockers [35,36]. SHG also reduces the response of wide
dynamic range neurons of the dorsal horn in response to
C-fiber stimulation and enhances opioid analgesia [17,37].
These findings suggest that SHG may be a useful adjunctfor the long term management of conditions with persist-
ing pain.
Long term transduction of non-dividing cells using
lentiviral vectors is an attractive approach to achieve
sustained release of therapeutic peptides in specific loca-
tions [38,39]. With the advent of third-generation lenti-
virus vector technology, in vivo gene therapy approaches
have become feasible [40]. This method uses the transfer
plasmid pRRL that contains the enhancer and promoter
from the U3 region of RSV joined to the R region of the
HIV-1 LTR.
Because the first synapses between the primary noci-
ceptor and the second order projection neuron are
present in the dorsal horn, the spinal cord could be an
attractive target to block nociceptive information and re-
duce the perception of pain. With this rationale, the goal
of the present study was to determine whether the com-
bination of lentiviral vectors for transfer of genes encod-
ing endomorphins and SHG into the spinal cord would
be a promising candidate therapy for attenuation of
neuropathic pain following spinal cord injury [41].
Results
Expression of endomorphins and serine histogranin in
neuroblastoma cell line
A schematic of the recombinant constructs is shown in
Figure 1. To confirm the expression of the genes from
the constructs, we used a human neuroblastoma cell line
(SH-SY5Y). The transduction of the peptide encoding
viral vectors was confirmed at five days by immunofluor-
escence. Using antibodies specific to endomorphins and
serine histogranin, numerous positive cells were detected
(Figure 2). The pattern of fluorescence of the peptide in
Figure 2 Lentiviral transduction of neuroblastoma cell line. Lentiviruses encoding SHG or Endomorphins were used to transduce a
neuroblastoma cell line (SH-SY5Y). 5 days post-transduction cells were fixed and stained with anti-SHG or anti-endomorphins (1 and 2) antibodies. An
image of negative control shows the absence of fluorescence (A). The culture was counter stained DAPI (blue) to identify nuclei (B). Green
fluorescence in (C) and red fluorescence in (D) correspond to SHG and Endomorphin 1 or 2 respectively. Micron bar = 50 μm.
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horn of spinal cord after injection of the vectors.
Effects of viral injection on motor function
The effect of spinal cord injury and the intraspinal injec-
tion of vectors on motor function was evaluated by the
BBB test (Figure 3). Before SCI the BBB locomotor score
for rats was 21, indicating coordinated fore and hind
paw movement, consistent toe clearance from the walk-
ing surface and trunk stability [42]. One week after SCI
surgery, the BBB rating was about 9, which indicated
plantar placement of the paw with weight support in
stance only or stepping with the dorsal but not plantarFigure 3 Locomotor scores after lentiviral injection in SCI rats.
Effect of spinal cord injury (SCI) and injection of viral vector encoding
GFP (n = 8) or a mixture of endomorphins and SHG (n = 10) injected
two weeks after injury on BBB locomotor scores. Rats were tested prior
to spinal compression (BL), one week after spinal compression (SCI),
before viral injection and then weekly following injection for 7 weeks.
Values are expressed as the mean ± S.E.M. No significant difference was
observed between the two groups.surface of the hind paw. No further changes in locomotor
function were observed two weeks following compression
surgery. By 7 weeks after injection BBB scores increased
to 11–12, which indicates frequent to consistent weight
support with plantar steps and no or occasional fore-
hindlimbs coordination. No significant differences were
observed between the rats that received the mixture of vi-
ruses and the rats that were injected by control viruses for
the 9 week observation period (P > 0.05). To verify if
intraspinal injection itself has any effect on the motor be-
havior of the animals we evaluated the BBB scores in ani-
mals with SCI and without vector injection. The results
showed no significant difference between this group of an-
imals and animals receiving viral vectors. No other obvi-
ous side effects of the treatment were noted.
Effects of viral injection on tactile and cold allodynia
Before SCI there were no significant differences among 5
groups in paw withdrawal threshold in the tactile allodynia
test with von Frey filaments, or in the percentage of with-
drawal responses in the acetone test for cold allodynia
(Figure 4, P > 0.05). Figure 4A shows changes in von Frey
responses over the 7 week time course following viral vec-
tor injections (overall F (df 4,9) = 7.941, P < 0.05). In this
test, significant differences were observed by 6–7 weeks
after injection (8–9 weeks post SCI) for the rats injected
with the mixture of EMs and SHG compared to the con-
trol/GFP- injected animals (p < 0.001). No significant ef-
fects were observed among the other groups injected with
single vectors or control GFP injected animals (Figure 4A,
P > 0.05). Figure 4B shows changes in responses to cold
(acetone test) over the 7 week time course following viral
vector injections (overall F (df 4,9) = 3.875, P < 0.05). In
the acetone test, significant differences were observed
Figure 4 Tactile and cold allodynia after lentiviral injection in SCI rats. Tactile allodynia in the von Frey test (A) and cold allodynia in the
acetone test (B) in SCI rats after lentiviral injection of GFP (n = 8), EM-1(n = 8), EM-2 (n = 8), SHG (n = 8) and EMs + SHG (n = 10) at 2 weeks after
SCI. Values are expressed as the mean ± S.E.M. *p < 0.05; **p < 0.01; ***p < 0.001 for EMs + SHG vs GFP groups. ##p < 0.01; p < 0.001 for EM1 vs
GFP groups.
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EM-1 compared to GFP group. At the later time points,
the mixture of EMs and SHG significantly reduced the
pain related behavior compared to the other groups
(P < 0.001 compared with control vector at 6–7 weeks
after injection).
Effects of viral injection on the mechanical and heat
hyperalgesia
The Hargreaves plantar test was performed to determine
whether viral injection affects thermal hyperalgesia. Before
SCI surgery the paw withdrawal latency in all groups
of animals was almost the same ranging from 16.48 ±
0.85 sec in control/GFP injected animal to 19.78 ±
0.45 sec in the group which received viral vectors encod-
ing SHG (Figure 5A). No significant differences in baseline
withdrawal latency were observed among animals in dif-
ferent groups (P > 0.05). Injection of the mixture of the
vectors prolonged the paw withdrawal latencies beginning
one week after injection and there was significant differ-
ence between this group with the control group injected
with control/GFP (P < 0.001). The differences in the with-
drawal latency between these two groups continued until
the end of the experiment (P < 0.001). Attenuation of heat
hypersensitivity was observed in all of the individual viralvector treated groups (SHG, EM-1, EM-2) compared to
control GFP injection throughout the experiment (overall
F(df 4,9) = 37.9; P < 0.05).
Mechanical nociceptive threshold, an index of
mechano-hyperalgesia, was assessed by the pressure
stimulation method as described by Randall and Selitto
[43]. SCI resulted in the development of mechanical
hyperalgesia as reflected by a significant decrease in the
hind paw withdrawal threshold in the paw pressure test.
A significant increase in mechanical threshold was ob-
served between the mixed viral vector group and control
animals injected with GFP vector during the 1–5 week
post-injection points although this was modest and vari-
able over time (Figure 5B). Significant differences be-
tween GFP and single-vector injected groups were
observed as well with modest, but significant differences
at some time points (overall F(df 4,9) =10.1).
Effect of delayed injection of viral vectors on pain
behavior
To mimic clinical scenarios, the effect of time of delivery
of therapeutic agents in chronically injured animals has
to be considered. Therefore we evaluated the analgesic
effect of intraspinal injection of our vectors at early
(2 weeks) and delayed (6 weeks) time points post SCI.
Figure 5 Thermal and mechanical hyperalgesia after lentiviral injection in SCI rats. Thermal hyperalgesia in the plantar test (A) and
mechanical allodynia in the Randall-Selitto test (B) in SCI rats after lentiviral injection of GFP (n = 8), EM-1(n = 8), EM-2 (n = 8), SHG (n = 8) and
EMs + SHG (n = 10) at two weeks after SCI. Values are expressed as the mean ± S.E.M. *p < 0.05; **p < 0.01; ***p < 0.001 for EMs + SHG vs GFP.
+++p < 0.001; ++p < 0.01; +p < 0.05 for SHG vs GFP; ###p < 0.001; ##p < 0.01; #p < 0.05 for EM1 vs GFP. ∙∙∙p < 0.001; ∙∙p < 0.01; ∙p < 0.05 for EM2
vs GFP.
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assessment of behavioral sensitivity after transplantation
of the mixture of the vectors (SHG, EM-1, EM-2)
showed nearly no differences in the ability to produce
antinociception whether the vector administration oc-
curred at 2 weeks or 6 weeks following injury (p > 0.05
for all behavioral tests). The only difference was detected
at 5 weeks post injection for mechanical hyperalgesia,
when animals injected at 2 weeks post SCI showed sig-
nificantly higher sensitivity to mechanical pressure than
animals injected at 6 weeks (p < 0.05). The reduced
pain-related responses achieved in the animals receiv-
ing intraspinal injection of combined EMs and SHG by
the end of the study (7 weeks following vector admin-
istration) was similar in both groups (p > 0.05).
Effects of naloxone or SHG antibody on viral vector
mediated attenuation of SCI allodynia
The effects of intrathecal injection of the opioid receptor
antagonist naloxone and an SHG antibody on the re-
duced cold and mechanical responses in animals with
viral injection encoding endomorphins and SHG two
weeks after SCI are shown in Figure 7. Naloxone re-
versed the antinociceptive effects of viral vectors, asindicated by a significant drop in withdrawal threshold
(Von Frey test) and increased sensitivity to cold sti-
muli (acetone test) compared to pre-injection responses
(P < 0.01, t-test). Injection of anti-SHG did not have any
effect on the mechanical thresholds measured by von
Frey filaments, but anti-SHG injection increased cold
allodynia in treated animals (P < 0.001, t-test).
Endomorphins and serine histogranin are expressed in
dorsal horn of the spinal cord
Based on the behavioral results, we examined the ex-
pression of the endomorphins and serine histogranin in
the dorsal horn of the spinal cord seven weeks after
viral vector injection. Sections were labeled for endo-
morphins or SHG immunoreactivity. Immunoreactive
positive cells for SHG (A) and endomorphins (B) were
seen in the dorsal horn at the 7th week after viral injec-
tion (Figure 8). Peptide immunoreactivity appeared as
light cytoplasmic immunostaining (red) with stronger
intensity at the surface of the cell bodies of the trans-
duced cells. No signal was found for SHG, and only low
signal for EMs was observed in control animals without
injection. In control animals receiving the control GFP
viral vector injection, GFP fluorescence was apparent in
Figure 6 Behavioral outcome of early and late injection of lentiviral constructs. Tactile allodynia in the von Frey test (A), cold allodynia in
the acetone test (B), thermal hyperalgesia in the plantar test (C) and mechanical hyperalgesia in the Randall-Selitto test (D) in SCI rats after viral
injection encoding endomorphins + SHG injected at early (two weeks, n = 10) or late (6 weeks, n = 12) time points after SCI. Values are expressed
as the ± S.E.M. There were no statistical differences observed between early and late SHG-EM injections comparing the data up to 7 weeks post
injection, with the exception of week 5, when the threshold for mechanical allodynia was significantly higher in the group injected early post
SCI. *p < 0.05.
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(Figure 9B and E), but there was no immunoreactivity
for SHG (Figure 9A). Endogenous EM1/2 immunoreac-
tivity was present in processes in the superficial dorsal
horn (Figure 9D), but was not co-localized with the
GFP (Figure 9F).
Additional staining was performed to detect possible
phenotypes of the transfected cells at 2 weeks post in-
jection of lentivectors with SHG or EM using mRFP
(red) reporter. High magnification images show indivi-
dual labelled cells following injection of Lenti/SHG
(Figure 10A) or Lenti/EM-2 (Figure 10D), both with
punctate distribution as found in the in vitro staining.
A subpopulation of these cells co-localized with the neur-
onal marker NeuN (Figure 10B and E; co-localization in
Figure 10 C and F).
In the spinal cord of animals injected with either
SHG or EM lentivectors (Figure 11A and D, respect-
ively), co-localization was also observed in some astro-
cytes (GFAP; Figure 11B and E; merged with mRFP
reporter in Figure 11C and F).
These data suggest that lentivectors used in this study
transfect both neuronal and non-neuronal cell popula-
tions. However, based on our observations thus far, it ap-
pears that neuronal cells are transfected at higher levels
than glial cells.Immunodot-blot analysis
The immunodot-blot analysis (Figure 12) indicated the
presence of EMs (A) and SHG (B) in cerebrospinal fluid
of the animals injected with the viral vectors and the pres-
ence of SHG in the spinal cord tissue of treated animals
(C). The intensity of the immunoreactive spots showed a
concentration dependency and was proportional to the
amount of the peptides. These results confirm that the
protein can be secreted following expression of the trans-
gene by transduced cells in the spinal cord.
Discussion
In this study, we have evaluated the analgesic properties of
a combination of virally encoded opioid peptides EM-1,
EM-2 with the NMDA antagonist SHG after their intrasp-
inal injection. The expression was similar to that seen pre-
viously with these constructs in different cells [44]. The
results showed that intraspinal delivery of the viral vectors
mixture produced marked attenuation of neuropathic pain
syndromes which lasted up to two months post injection.
Antinociceptive effects of intraspinal injection of lentivi-
ruses encoding EMs and SHG on mechanical and cold
allodynia appeared to develop with a gradual onset by five
weeks after injection. In contrast, heat and mechanical
hyperalgesia attenuation were achieved by the first week
following injection. Early transgene expression following
Figure 7 Effect of Naloxone on tactile and cold allodynia in treated rats. Mechanical allodynia (A and C) in the von Frey test and cold
allodynia (B and D) in the acetone test before and after intrathecal administration of naloxone (A and B) and anti-SHG (C and D) in SCI animals
treated 2 weeks after SCI with mixed EMs/SHG vectors. Values are expressed as the mean ± S.E.M. **P < 0.01, ***P < 0.001 compared to pre injection
values. (n = 8, t-test).
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other studies. The antinociceptive effects were sus-
tained through the remainder of the study (7 weeks)
and could be transiently reversed by intrathecal admin-
istration of anti-serine histogranin antibody and theFigure 8 Immunohistochemical detection of SHG and EMs in the spin
spinal cord sections from animal transduced with viral vector as indicated
fluorescence) of SHG (A) or EM 1/2 (B). Spinal cord of a control untransduc
C. Panels D, E, and F represent the higher magnification of rectangles of Aopiate antagonist naloxone, suggesting the participation
of opioid and NMDA receptors in the observed effects.
Gene therapy has several benefits compared to trad-
itional pharmacological therapy. The use of viral vectors
offers a potential therapeutic option for treatment ofal cord of treated rats. Representative images of immunostained
above the image (A-B) two weeks after SCI show expression (red
ed animal immunostained with endomorphin antibodies is shown in
, B and C, respectively. Arrows indicate some of the expressing cells.
Figure 9 Injection of control vector expressing GFP only. No SHG signal was detected in spinal cords of animals receiving control GFP vector
injection (A). Staining with EM1/2 in these animals revealed punctate staining of the endogenous EM in the dorsal horn (arrows in D). B and E
show the GFP fluorescence in cell bodies and processes in the same sections (A and D, respectively). C and F are merged images to reveal
any co-localization.
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proaches may be a useful method to achieve continuous
local expression of short lived analgesic peptides in the
spinal cord and are being considered for clinical applica-
tion. Many of the previous studies have utilized herpes
simplex viruses (HSVs) as a delivery vector in pain treat-
ment. In the rodent CCI neuropathic pain model, an in-
crease in paw withdrawal latencies to mechanical and
thermal stimulus following application of recombinantFigure 10 Immunohistochemical detection of neuronal phenotype of
cells expressing reporter gene mRFP (red) with neuronal marker (NeuN, gre
in the cytoplasm of neuronal cells (C,F).defective herpes simplex viral vector encoding proenke-
phalin has been reported [45]. Also subcutaneous injec-
tion of HSV encoding preproenkephalin to the plantar
surface of the paw increased the nociceptive threshold in
phase II of the formalin test [46].
Recently, a Phase I clinical trial of HSV-mediated gene
transfer of proenkephalin to the DRG was reported to
produce significant pain relief in patients with cancer
pain [47]. Endomorphin-2 has also been successfullytransduced cells. Co-localization of SHG (A) or EM2 (D) transduced
en)) (B,E). Overlapping images show the presence of punctate staining
Figure 11 Immunohistochemical detection of glial phenotype of transduced cells. Cells positive for astrocytic marker GFAP (B,E) co-labeled
with some of the SHG (A-C) or EM (D-F) transduced cells (full arrowheads in C,F). Open arrowheads mark non-GFAP positive cells transduced by
SHG or EM respectively.
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peripheral neuropathic pain in rats [48,49].
In addition to HSV vectors, pain modulator genes have
been delivered directly to the spinal cord using adeno-
associated viruses (AAVs) and lentiviruses [50-53].
The possibility of long-term expression of therapeutic
peptides in specific cells is especially attractive as a treat-
ment option for conditions such as SCI neuropathic
pain. Neuropathic pain is initiated or caused by multiple
etiological factors; therefore sustained simultaneous tar-
geting of several signalling pathways is likely necessary
to obtain effective analgesia. Lentiviral delivery is advan-
tageous in that both dividing and non-dividing cells canFigure 12 Immunodot-blot analysis of CSF and spinal cord of treated
and SCI animals injected by a mixture of viral vectors encoding SHG and E
amount of each peptide spotted is indicated in the column on the left side o
B: reactivity of CSF with SHG antibody. C: detection of SHG in the spinal cordbe reached; it confers long-term stable expression of
transgenes encoding naturally occurring peptides without
detectable pathology and shows low immunogenicity
[54,55]. In other studies using lentiviruses, no increase in
inflammatory markers like interleukin-mRNA was seen
[56] [50]. Considering these advantages, reproducibility,
and safety, we chose the lentivirus-mediated gene therapy
system as an initial proof-of-concept in this study.
The spinal cord clip injury model used in this study is
a clinically relevant model of chronic pain in SCI pa-
tients [57]. Rats in this model exhibit robust withdrawal
responses to innocuous and noxious stimulation of their
hind paws, consistent with the presence of allodynia andrats. Immunodot-blot assay of CSF from the GFP control SCI animals
Ms. No reactivity was seen in the CSF of GFP control SCI animals. The
f each panel. A: reactivity of CSF with endomorphin 1 and 2 antibody,
homogenate from EMs + SHG treated animals.
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bothersome and difficult to treat in patients with both
incomplete and complete SCI. This model has shown
good predictive validity using a variety of pharmacologic
agents, including those with some or no reported pain-
reducing benefits in SCI pain patients [57].
Endomorphins inhibit nociceptive transmission in the
spinal cord through μ-opioid receptors which are localized
in neuronal circuits involved in processing of nociceptive
information [27]. Despite a distinct anatomical distribu-
tion of endomorphins with EM-1 present mainly in the
brain and EM-2 in the spinal region rich in μ-opioid re-
ceptors [58], both actively participate in nociceptive trans-
mission after peripheral stimuli. Antinociceptive effects of
the intrathecal injection of EM-1 or EM-2 were observed
in models of peripheral nerve injury [18,31].
NMDAR is another potentially promising target for
enhancing analgesic activity. NMDAR in the superficial
dorsal horn has been implicated as a major contributor
to excitatory nociceptive transmission [59]. Substantial
evidence has established that activation of the NMDAR
in the spinal dorsal horn is essential for central
sensitization [60,61]. SHG was identified in a screen for
compounds that enhanced adrenal transplant-mediated
analgesia in rat pain models [62]. It is a stable synthetic
analogue of histogranin with NMDA antagonist activity
and has the potential to be delivered recombinantly on a
long-term basis using emerging lentiviral technologies.
Intrathecal administration of SHG blocks the hyperalge-
sia and allodynia produced in rats by intrathecal NMDA
administration with no motor side effects [35,63]. This
finding is especially important from a clinical view, as
the intrathecal administration of NMDA receptor antag-
onists, such as ketamine, has a promising role in patients
that are poorly responsive to traditional analgesics [64].
The use of an NMDA receptor antagonist in pain ther-
apy is often accompanied by motor deficits which limit
their potential therapeutic value for neuropathic pain
management. In the current study, deleterious motor
side effects induced by the lentiviral injection encoding
SHG were not observed. Similarly, in previous studies
using bolus intrathecal SHG injection, locomotor side
effects were not observed in contrast to other NMDA
antagonists [17]. Using the clip compression model, rats
develop a partial paralysis due to SCI with modest pro-
gressive recovery, as observed with the BBB test. The BBB
test scores of animals injected with EMs and SHG lentivi-
ruses were comparable to those without injections and
with the animals injected with the control GFP lentivirus.
Behavioral tests for tactile, thermal and mechanical
hypersensitivity revealed beneficial effects of combined in-
jection of EMs and SHG on SCI induced pain. The anal-
gesic effect was observed as soon as 1 week post injection
for some modalities, and sustained for at least up to7 weeks, when the behavioral study was terminated. Inter-
estingly, only modest effects, at best, were observed with
individual peptide vectors. This may be due to the local
levels of available peptides that can be achieved by the
viral vectors, perhaps insufficient for reducing neuropathic
SCI pain. Previous findings in our lab have indicated that
the blockade of spinal NMDA receptors alone, via bolus
intrathecal injection of either SHG or another NMDA an-
tagonist ketamine, is insufficient in reducing neuropathic
pain symptoms in the SCI clip compression model [57].
Thus, it is perhaps not surprising that vector delivery of
SHG alone was ineffective in reducing SCI pain in the
current study. Both SHG and the EMs have reported ef-
fectiveness in numerous other pain models, although re-
cent findings in our lab has shown that these effects are
variable depending on the selected models and outcome
measures [18]. It is likely that the labile nature of small
neuropeptides limits their time course and efficacy; thus a
gene therapy approach may be ideal in overcoming this
limitation.
Although the intrathecal injection of endomorphins
alone have not been evaluated in the SCI clip compression
model, a possible explanation for their limited effective-
ness alone using the viral vector approach in the current
study is the potential development of tolerance to contin-
ued exposure to these mu-opioids mediated by sustained
delivery from transduced spinal cells. If this is the case, re-
sults of this study provide strong support for both the
additive effects and reduced tolerance development of this
combination strategy. In contrast to the singly delivered
peptides, when co-delivered using the combined SHG and
EM viral vectors, potent analgesic effects, once initiated,
were maintained without decrement through the study
duration. The contributions of both the EMs and SHG in
mediating the sustained analgesic effects of the viral vec-
tors is supported by the reversal using intrathecal injection
of opioid (naloxone) or NMDA antagonist (anti-SHG).
The time of delivery of therapeutic compounds in SCI
model is an important issue because delayed onset of the
pain treatment after SCI is clinically more relevant than
early interventions. In this study we showed that the de-
layed treatment using viral vector-mediated delivery of an-
algesic peptides could still be effective in alleviating SCI
neuropathic pain. The reduced pain responses in animals
receiving intraspinal injection of EMs and SHG 6 weeks
after SCI were similar to the reduced pain responses of
animals receiving the injections on the second week after
SCI. This suggests that delayed injection of lentiviral vec-
tors encoding the appropriate analgesic peptides can still
alleviate chronic pain in SCI models.
Conclusions
In conclusion, the present series of studies provides
evidence that SCI-induced neuropathic pain may be
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duction and release of an NMDA antagonist peptide and
endomorphins.
Given that this type of neuropathic pain is especially dif-
ficult to treat, the success of this gene therapy approach is
significant [65]. The long term effect of intraspinal admin-
istration of lentiviral vectors encoding SHG and endomor-
phins provide support for the concept that such combined
therapy can indeed control enhanced pain states without
overt adverse effects. The prolonged analgesic effects
observed here also suggest the lack of tolerance develop-
ment using this strategy, an important feature for poten-
tial clinical application in long term pain management.
Methods
Construction of the lentiviral vectors encoding SHG
and EMs
The generation and characterization of the SHG construct
has been previously published [44]. Similar approaches
were used for constructs encoding endomorphins [66].
Briefly, peptide sequences of EM-1 and EM-2 were reverse
translated. Sense and anti-sense oligonucleotide primers
(Sigma Genosys, Miami) were synthesized and annealed
to produce double stranded DNA (dsDNA) sequence cod-
ing flanked by Bgl II/Sal I half sites, encoding either EM-1
or EM-2 As endomorphins are endogenously amidated,
these oligos include a glycine before the stop codon. Pep-
tides with extended glycine are substrates for the amida-
tion complex.
These constructs were subcloned into lentiviral vectors
and high titer purified recombinant lentiviruses encoding
either SHG, or EM-1 or EM-2 were generated by the in
house viral vector core. Briefly, viral stocks were produced
by co-transfecting SHG/pRRL or EM/pRRL with pack-
aging vectors in 293 T cells. Three packaging plasmids
(self-inactivating vector plasmid, third generation pack-
aging plasmid and an envelope plasmid, pLP1, pLP2, and
pLP/VSVG) supply the structural and replication proteins
in trans that are required to produce the lentivirus. Con-
trol lentiviruses were generated at the same time by co-
transfecting the 293 T cells with the identical 3 packaging
plasmids and pRRLs in PPT.CMV.WPRE containing the
720 bp GFP (GFP/pRRL). Vector batches were tested for
the absence of replication-competent virus by monitoring
p24 antigen expression in the culture medium of trans-
duced 293 T cells for 2 weeks as an additional safety
check. Viral p24 antigen concentration was determined by
ELISA (PerkinElmer, Boston, MA). In all cases tested, p24
was undetectable and transducing activity was expressed
in transducing units (TU). Nerve growth factor signal se-
quence gene (preproNGF-β) was used for the recombin-
ant peptide to be targeted to the secretory apparatus of
the cells and consequently get secreted as previously re-
ported [44,66,67]. All construct sequences were confirmedby the Genewiz sequencing facility using gene-specific
primers (sense primer 5’-TTGGATCC GCGTAATGTC
CAATGTTGT-3’ and anti-sense primer 5’-AGTCTA
GACA TAAAGCCTCCGTATACT-3’) to verify presence
and expected sequence of each recombinant gene and in
polymerase chain reaction as previously published [66].
In order to visualize transfected cells in vitro, some of
the SHG and EM-1 and EM-2 constructs were sub-
cloned into the lentiviral vector in the frame with a re-
porter gene mRFP using the protocol described above.
The following types of viral vectors were used:
1) The control viral vector containing only the GFP
(green fluorescent protein) gene (Lenti/GFP).
2) The viral vector containing SHG gene that encodes
the serine histogranin (Lenti/SHG with mRFP for
immunohistochemical detection.
3) The viral vector containing endomorphin gene
that encodes EM-1 (Lenti/EM-1 with mRFP for
immunohistochemical detection).
4) The viral vector containing endomorphin gene
that encodes EM-2 (Lenti/EM-2 with mRFP for
immunohistochemical detection).
Transgene viral expression in vitro
The schematic in Figure 1 shows the features of the lenti-
viral construct as previously published [66]. SH-SY5Y cell
lines were grown in DMEM/F12 medium (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS) and antibiotics. At 70% confluency the cells were
transduced with Lenti/endomorphins or lenti/SHG viruses
(108 transducing units per ml (TU/ml) based on viral coat
protein p24 ELISA assay. Five days after transduction the
cells were fixed for 10 minutes with 4% paraformaldehyde,
permeablized with phosphate buffered saline (PBS) with
0.1% Tween-20 (PBST) for 10 minutes and then stained
for endomorphins or SHG by standard immunofluores-
cence protocols using antibodies against EM-1/EM-2
(1:300, Genetex) and SHG (1:1000 , 21st Century Bio-
chemical). Briefly, cells were incubated in 5% normal goat
serum and then in primary antibody for one hour in each
step. After washing with PBS, secondary antibodies (1:300
dilution, Alexa-fluor 594 or 488 goat anti-rabbit, Invitro-
gen) were added for 30 minutes. Cells were washed in
PBS and incubated with 120 ToPro/DAPI for 10 min.
Finally, the slides were coverslipped with mounting
medium. Primary antibody was withheld from control
slides to determine background due to non-specific
staining.
Animals
Male Sprague–Dawley rats weighing 150–170 g at the
initiation of the studies were used. All animal procedures
followed NIH guidelines and were approved by the
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Committee.Surgeries
All the surgical procedures were performed under aseptic
technique in a special room design for surgery purposes.
For spinal cord injury, after anaesthesia with mixture of
isofluorane and O2, a laminectomy was performed at
T6–T8. The spinal cord was compressed by a micro-
vascular clip (Harvard Apparatus, MA) for 1 min. After
the one minute compression, the clip was removed
carefully (care was applied not to damage the dura or
spinal nerves), the muscles sutured with 4–0 chromic
gut (Ethicon Inc., Somerville, NJ) and wound clips were
used to close the skin. From the day after surgery the
bladder was manually expressed in the morning and
afternoon until the animals were able to express their
bladders independently.
Based on the analgesic effect of peptide SHG and mor-
phine [17] and the effectiveness of a ratio of synergistic
analgesic peptide combination [68] we chose to test the
mixture of EM-1/EM-2 and SHG at the same ratio i.e.,
3:3:1. Animals with 2-week old SCI were randomly allo-
cated to different viral vector-injected groups. The control
group received lentivirus encoding GFP. In a separate
group of animals, to explore whether delayed vector treat-
ment could still be effective on the alleviation of pain, the
mixture of endomorphins and SHG was injected six weeks
after SCI. For all injections, spinal cords at the level of
L3/L4 were exposed by laminectomy and each animal re-
ceived four injections of 20 ng/μl of lentivirus (108 TU/ml
based on p24 ELISA ) bilaterally (two per side) in the
spinal cord 1 mm apart. For animals receiving combined
vector injections, since the mixture of EM-1/EM-2 and
SHG were done at ratio 3:3:1, the individual doses in the
mixture were 8.6 ng EM1, 8.6 ng EM2, and 2.8 ng/ μl.
Injections were done stereotaxically (Kopf ) in a volume
of 1 μl/site (0.5 μl/min) at a depth of 0.3 mm from the
dorsal border and 0.7 mm from the midline using a
glass pipette attached to a 10-uL Hamilton syringe
mounted on a microinjector. To prevent backflow, the
needle was kept in its place for one minute after the
termination of the injection. To maximize reproducibility,
injections were performed by only 1 surgeon. The overly-
ing muscles were sutured by 4–0 chromic gut and the skin
was closed with wound clips. Animals were allowed to re-
cover at 37°C for 24 h, after which time they were
returned to the animal care facility.Behavioral tests
All the behavioral tests were done by evaluators who were
unaware of experimental groups. Animals were tested be-
fore spinal cord injury (SCI), one week after SCI, beforeintraspinal injection of the vectors and then every week
after for seven weeks.
Motor Function Recovery test
The Basso-Beattie-Bresnahan (BBB) test was used for
evaluation of motor behavior [42]. Rats were placed in the
center of an open-field area with a 4 foot diameter, and
the behavior of the animals was observed for a 4 min test
period by two individuals blinded to the treatment. The
scale was designed to reflect motor rating scores. Briefly,
the BBB scale involves closely monitoring limb movement,
weight-bearing capability, coordination, and gait. The
scores range from 0 to 21. Zero indicates complete paraly-
sis without joint movement and 21 indicates normal loco-
motion with full coordination and proper gait, movement
at all joints, full weight support, and appropriate limb,
body and tail positioning.
Sensory tests
For the assessment of mechanical and cold allodynia the
rats were placed on a metal mesh covered with a plastic
dome (13 × 17 × 28 cm) for at least 20 minutes before test-
ing. The thresholds for mechanical allodynia were mea-
sured with a series of von Frey filaments. The filaments
were applied to the plantar skin of the hindpaw and bent
slightly. Withdrawal of the paw, usually followed by lick-
ing of the paw or body movement, was recorded as a posi-
tive response. Eight specific calibrated von Frey filaments
were used via the up-down method to determine the with-
drawal threshold. The filaments with 0.25 g and 15 g force
were selected as lower and upper limit respectively. A
hind paw withdrawal from the filament led to the use of
the lower force filament. A lack of response led to the use
of the next higher force filament. If the strongest hair did
not elicit a response, the threshold was recorded as 15 g.
Both hind paws were tested and about 5 min separated
testing of the opposite paw.
Cold allodynia was measured as the number of foot
withdrawal responses after application of an acetone
drop to the plantar surface of the paw. Usually the nor-
mal rat did not respond to acetone application, but the
injured rats showed nociceptive responses, such as foot
shaking or biting. The testing was repeated five times
with an interval of approximately 3–5 min between each
test. The response frequency to acetone was expressed
as a percent response frequency ([number of paw with-
drawals/number of trials] × 100).
Thermal nociceptive threshold was assessed with the
method first described by Hargreaves et al. [69] using
the Plantar analgesiometer (Ugo Basile model 7371). At
the beginning of each testing day, animals were placed
in test cages for acclimation 30 min before. The testing
device used light from a slide-projector lamp passed
through a filter that allowed passage of only infra-red
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was positioned under the middle of the right or left hind
paw. Once in position, the heat source was activated,
which slowly heated the paw. On paw withdrawal, a
photo-cell automatically shut off the heat source and re-
corded the time to withdrawal.
To avoid causing a thermal injury in the event that the
animal did not withdraw its paw voluntarily, there was
an upper limit cut off of 25 sec after which the heat was
automatically terminated. If paw movement subsequent
to stimulus initiation appeared to be related to grooming
or locomotion, that trial was repeated after a lapse of
1 min. Testing was repeated 3 times for each paw with
at least 5 minutes interval between the trials and the
average of three trials per paw was used to report the
final withdrawal latency.
Mechanical hyperalgesia was measured using in-
creased mechanical pressure applied to the rat paw with
an analgesiometer (Ugo Basile) [43]. The rats were
wrapped in a towel and an increasing force (48 g/s) was
applied to the plantar surface of the hind paw until the
rat reacted with vocalization or started to exhibit the
flight or struggle response. The apparatus terminated at
1000 g (25 in scale units) in the absence of a response.
On all testing days the measurement of thermal sensitiv-
ity was followed by the measurement of sensitivity to
mechanical stimuli.
To assess pharmacologic mechanisms, some animals
received intrathecal injection of anti-serine-histogranin
(10 μl, 0.5 μg/ml) or naloxone (1 μg in 10 μl), and were
tested for mechanical and cold allodynia before and after
injection.
Direct transcutaneous intrathecal injections were used
by inserting a 25 G needle connected to a 25 μl
Hamilton syringe into the tissues between the dorsal as-
pects of L5 and L6 perpendicular to the vertebral col-
umn. This site was selected in order to reduce the
possibility of spinal damage and increase the interverte-
bral accessibility. In this location the spinal cord termi-
nates and the cauda equina begins. Sudden lateral
movement of the tail was used as an indicator of suc-
cessful puncture. Naloxone was dissolved in saline and
injected in a volume of 10 μl. After injection the syringe
was held in position for a few seconds and then removed
slowly to avoid any outflow of the drug. Cold and mech-
anical allodynia assessment was done 15 min after
injection.
Immunohistochemistry
Rats were deeply anesthetized with a mixture of Ketamine
and Xylazine (100 and 40 mg/kg respectively, ip) and
perfused transcardially with saline, followed by 4% para-
formaldehyde in 0.1 mol/L phosphate buffer at pH 7.4.
Spinal cords were removed and immersed in the samefixative overnight in 4°C, and transferred to 25%
sucrose in phosphate buffer for cryoprotection. Twenty-
micrometer-thick sections were rinsed in phosphate-
buffered saline (PBS) and Tris buffer saline, incubated in
filtered 2% sodium paraperiodate in TBS for 20 min. Sec-
tions were incubated in 5% normal goat serum (NGS) for
30 min, then overnight with primary antibody anti-SHG
(1:1000, 21st century biochemical), anti-NeuN (1:200,
Chemicon), anti-GFAP (1:200, Sigma). There is no com-
mercial source for anti-histogranin or anti-serine histo-
granin antibodies; therefore, a custom antibody for SHG
was generated for us with 21st Century Biochemicals. A
synthetic SHG peptide was used to immunize rabbits.
Based on our published data [44,66], anti-SHG antibody
showed a dose dependent reaction with the synthetic SHG
peptide. The specificity of the reaction was supported by
the lack of reaction of anti-SHG antibody (high titers) with
an irrelevant peptide, EM-1 [44] or anti-EM-1 and 2 anti-
body (3 μg/ml, Genetex) in PBS +% 0.4Triton X (PBST)
at 4°C. After washing with PBS, sections were incubated
in the appropriate secondary antibody (1:300 dilution,
Alexa Fluor 594 and 488 goat anti-rabbit and Alexa Fluor
488 goat anti-mouse, Invitrogen) for 2 h. Tissue sections
were washed in PBST and 120 ToPro/DAPI was added for
10 min. Finally, the sections were coverslipped with fluo-
rescence mounting medium.
Immunodot-blot
A sample of cerebrospinal fluid (CSF) of animals
injected with the vectors was collected from the cisterna
magna. Briefly, the atlanto-occipital membrane between
the occipital bone and the upper cervical vertebra was
exposed by a small incision in the skin and overlying
muscle. A needle connected to an insulin syringe was
inserted slightly into the membrane and a clear CSF
sample was drawn without any blood contamination.
The immunodot-Blot procedure was adapted from
Abcam Company. The stock solution of EM-1, EM-2
and SHG peptide were prepared with saline. Serial dilu-
tion of each peptide was prepared in concentrations ran-
ging from 0.25 μg/μl to 0.008 μg/μl for SHG and from
1 μg/μl to 0.03 μg/μl for endomorphins. 2 μl of each
sample was spotted on the 0.22 μ pore-size nitrocellu-
lose membrane separately. Serial dilution of the CSF of
animals injected with Lenti/SHG and EM-1/EM-2 was
prepared and 2 μl of each samples spotted on the mem-
brane. After air drying at room temperature, the mem-
branes were incubated in blocking serum containing 5%
bovine serum albumin (BSA) in Tris-buffered saline with
0.4% triton (TBST) for one hour before being transferred
into the primary antibody. The same primary antibodies
with the same dilution in the immunohistochemistry
protocol were used. Membranes were incubated in pri-
mary antibody for 30 min before washing with PBST for
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secondary antibody conjugated with horse-radish pero-
xidase (HRP) (1:10000 anti-rabbit IgG-HRP Santa Cruz
Biotechnology) for 30 minutes at room temperature. After
washing with PBST, enhanced chemiluminescent sub-
strate (ECL, Thermo Scientific) was used for detection of
HRP. Membranes were incubated in ECL for 1 min and
then exposed to X-ray film in the dark room.
Statistical analysis
The results are presented as mean ± SEM. Statistical
analysis of data was carried out using GraphPad Prism.
Data were compared among groups with two-way ana-
lysis of variance with repeated measures ( RM ANOVA)
followed by the Bonferroni post hoc test and by t-test.
Statistical significance was assumed when P < 0.05.
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